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Abstract
Introduction Human cathelicidin antimicrobial protein,
hCAP18, and its C-terminal peptide LL-37 is a multifunctional
protein. In addition to being important in antimicrobial defense,
it induces chemotaxis, stimulates angiogenesis and promotes
tissue repair. We previously showed that human breast cancer
cells express high amounts of hCAP18, and hypothesised that
hCAP18/LL-37 may be involved in tumour progression.
Methods hCAP18 mRNA was quantified in 109 primary breast
cancers and compared with clinical findings and ERBB2 mRNA
expression. Effects of exogenous LL-37 and transgenic
overexpression of hCAP18 on ErbB2 signalling were
investigated by immunoblotting using extracts from breast
cancer cell lines ZR75-1 and derivatives of MCF7. We further
analysed the impact of hCAP18/LL-37 on the morphology of
breast cancer cells grown in soft agar, on cell migration and on
tumour development in severe combined immunodeficiency
(SCID) mice.
Results The expression of hCAP18 correlated closely with that
of ERBB2 and with the presence of lymph node metastases in
oestrogen receptor-positive tumours. hCAP18/LL-37 amplified
Heregulin-induced mitogen-activated protein kinase (MAPK)
signalling through ErbB2, identifying a functional association
between hCAP18/LL-37 and ErbB2 in breast cancer.
Treatment with LL-37 peptide significantly stimulated the
migration of breast cancer cells and their colonies acquired a
dispersed morphology indicative of increased metastatic
potential. A truncated version of LL-37 competitively inhibited
LL-37 induced MAPK phosphorylation and significantly reduced
the number of altered cancer cell colonies induced by LL-37 as
well as suppressed their migration. Transgenic overexpression
of hCAP18 in a low malignant breast cancer cell line promoted
the development of metastases in SCID mice, and analysis of
hCAP18 transgenic tumours showed enhanced activation of
MAPK signalling.
Conclusions Our results provide evidence that hCAP18/LL-37
contributes to breast cancer metastasis.
Introduction
The human cathelicidin antimicrobial protein hCAP18 is the
single human member of the mammalian cathelicidin family of
proteins [1]. The holoprotein consists of a conserved prodo-
main, cathelin and the non-conserved C-terminal peptide LL-
37, which is enzymatically cleaved after secretion [2-4].
Consistent with a role in the first line of defense, hCAP18/LL-
37 is widely expressed in leucocytes and in epithelial cells
[5,6]. Although initially identified purely as an antimicrobial pro-
tein, hCAP18/LL-37 is multifunctional with diverse and signif-
icant effects on eukaryotic cells. Thus, LL-37 transactivates
the epidermal growth factor receptor (EGFR) inducingPage 1 of 13
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otaxis and angiogenesis through the G-protein coupled recep-
tor, the formyl peptide receptor like-1 (FPRL-1) [9-11]. In line
with these findings, current research indicates that hCAP18/
LL-37 is actively involved in tissue repair and wound healing
[12,13] processes that share fundamental biological features
with tumour growth and progression [14].
Antimicrobial proteins, including hCAP18/LL-37, have prima-
rily been proposed as potential anti-tumour agents based on
their cytotoxic effects at high concentration [15,16]. However,
in a previous study comprising 28 breast cancer samples, we
reported that hCAP18/LL-37 was upregulated in breast can-
cer cells with a correlation between hCAP18 protein levels
and tumour grade, whereas in normal mammary tissue it was
produced at a low level [17]. We also found that treatment
with LL-37 peptide stimulated the proliferation of epithelial
cells suggesting that LL-37 may act as a growth factor. Recent
findings in lung and ovarian cancer show that overexpression
of hCAP18/LL-37 also occurs in other cancer forms and may
promote tumour growth [18,19].
Based on our previous study, we were prompted to further
explore the role of hCAP18/LL-37 in breast cancer. Here we
report the coexpression of hCAP18 and ERBB2 in breast




Breast cancer samples were collected consecutively from
patients treated at Danderyd's Hospital, Stockholm, Sweden
between 1994 and 1998 (n = 145). Thirty-six samples were
excluded due to lack of information about oestrogen receptor
(ER) status, lymph node status and/or RNA. The remaining
109 tumours were scored following established guidelines,
and ER status was assessed on routinely processed paraffin
sections. Healthy breast tissue was obtained from patients
undergoing reconstructive surgery (n = 4). The study was
approved by the regional committees of ethics and informed
consent was obtained from patients and controls.
Expression analysis of tumour RNA
RNA from human breast cancers was extracted with Trizol
(Invitrogen, Paisley, UK) and from mouse tumours with a col-
umn-based extraction kit (Bio-Rad Laboratories, Hercules, CA,
USA). Random primed reverse transcription and real-time
PCR (RT-PCR) analysis for hCAP18 were performed as pre-
viously described, using 18S RNA for normalisation [17].
ERBB2 transcription was quantified using an Assay-on-
Demand mixture (Applied Biosystems, Foster City, CA, USA).
Statistical analyses
Levels of hCAP18 were compared with respect to lymph node
and ER status by means of analysis of variance (ANOVA).
Pearson correlation coefficients were used to assess the
association between hCAP18 and ERBB2. All analyses were
performed on logarithmically transformed data using the Sta-
tistical Analysis System package, version 9.1 (SAS Institute
Inc, Cary, NC, USA). For quantitative evaluation of cell colo-
nies grown in agar, experiments using eight plates for each
condition were arranged in a factorial design and the resulting
data analysed by ANOVA with the significance level set to α =
0.05. For statistical evaluation of cell migration and mouse
tumours and the occurrence of metastases, the non-paramet-
ric Mann-Whitney test was used.
Cell lines
ZR75-1 and MCF7 were obtained from ATCC (via LGC Pro-
mochem, Boras, Sweden). The cell line MJ1105 [20], derived
from MCF7 cells, was kindly provided by Mikala Egeblad,
UCLA, San Francisco, USA. Cells were stably transfected
with a vector for bicystronic expression of enhanced green flu-
orescent protein (eGFP) and hCAP18 (cell line named
MJ1105-hCAP) or with the empty eGFP-control (cell line
named MJ1105-eGFP), selected by growing in OptiMEM sup-
plemented with 10% FCS and G418 (400 μg/ml), enriched by
fluorescence-activated cell sorting (FACS) selection for eGFP
expression and maintained as described [17].
Synthetic peptides
LL-37, LL-25 and scrambled peptide were synthesised and
purified by HPLC to a purity of 98% (Polypeptide Laboratories
Hilleröd, Denmark, and GeneCust, Dudelange, Luxembourg).
The biological activity of LL-37 was confirmed in an antibacte-
rial assay (not shown).
Mitogen-activated protein kinase activation assay
All experiments were performed on at least two independent
occasions. ZR75-1 cells or MJ1105 derivatives were plated in
12-well plates at 100,000 cells per well, and starved for 48
hours in DMEM without FCS. Cells were stimulated with LL-
37 and/or Heregulin β3 (HRG) recombinant protein (Upstate,
Lake Placid, NY, USA). HRG was used at 2 ng/ml to optimise
detection of synergism between HRG and LL-37. The inhibi-
tors bisindolylmaleimide I, PD153035, GM6001, H89, PP2
(all Calbiochem, San Diego, CA, USA), N-acetylcystein, Tiron
and pertussis toxin (all Sigma, St Louis, MO, USA), and
WRW4 (Phoenix Pharmaceuticals, Belmont, CA, USA) were
applied at the indicated concentrations 30 minutes before
stimulation with LL-37 and/or HRG. Cells were washed 20
minutes after stimulation with ice-cold PBS containing 1 mM
sodium fluoride, 100 μM sodium orthovanadate and 2 mM
phenylmethylsulphonylfluoride, and immediately lysed with
sodium dodecylsulfate lysis buffer containing the respective
inhibitor plus 50 mM dithiothreitol.
Protein detection
Western blot analysis was essentially performed as described
[13], using antibodies against phosphorylated and total pro-Page 2 of 13
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Technology, Beverly, LA, USA), phosphorylated and total pro-
tein ERBB2 (Upstate, Lake Placid. NY, USA), and hCAP18
[13], all at 1/2000 dilution. Enhanced chemiluminescence sig-
nals (Amersham Biosciences, Piscataway, NJ, USA) were
captured by a charge-coupled device camera (Fujifilm, Tokyo,
Japan) using Image Gauge (Fujifilm, Tokyo, Japan) for evalua-
tion. Linearity of the signal within the range of our experiments
was confirmed using a serial dilution. For normalisation, the
Ponceau staining of the blot was scanned and the digitised
picture evaluated with the same software. The linear portion of
the signal was determined to occur between 5 and 100 μg of
total protein extract, therefore about 20 μg was routinely
applied.
Immunohistochemistry on cryostat sections from snap-frozen
tumours was performed as described previously [13] with
affinity purified rabbit anti-LL-37 antibodies at 1/6000 dilution.
The presence of breast cancer cells in all tumours and metas-
tases was verified by immunohistochemistry with anti-human
leucocyte antigen (HLA) A/C antibodies (Serotec, Raleigh,
NC, USA) at 1/40,000 dilution.
Colony formation assay
One thousand cells (MJ 1105 or ZR75-1) were suspended in
2 ml of 0.35% melted agar in OptiMEM medium (Invitrogen,
Carlsbad, CA. USA) with 5% FCS plus LL-37/HRG, and
plated in 50 mm gridded dishes containing a solidified layer of
0.7% agar in the same medium. After 12 days, the top layer of
the culture was stained with 0.2% p-iodonitrotetrazolium violet
(Sigma, St Louis, MO, USA). Colonies within a grid of 10 × 10
that were larger than 100 μM in diameter (about 200 colonies/
plate) were counted and their morphology categorised. All
evaluations were performed in a blinded manner. The experi-
ments were independently performed three times.
Cell migration assays
The Boyden chamber migration assays were carried out in the
presence or absence of LL-37 and/or LL-25. Briefly, cells were
serum starved for four hours in 0.2% BSA containing α-MEM
medium. Cells were then trypsinised, harvested and resus-
pended in serum-free α-MEM medium. Chemotactic activity
was determined in a Boyden chamber system (Neuroprobe
Inc, Gaithersburg, MD., USA) with a 8 μm pore size polycar-
bonate membrane (Neuroprobe Inc, Gaithersburg, MD., USA)
separating the two chambers. Serum-free α-MEM alone or
with LL-37 and/or LL-25 was added to the lower chamber with
final concentrations of 2 μM and 1 μM, respectively. Cells
were loaded to the upper chamber at a concentration of 5 ×
104 cells in 500 μl of serum-free α-MEM. Chambers were
incubated at 37°C for five hours in a 95% air, 5% carbon diox-
ide atmosphere. The upper medium was then removed, the
chamber was disassembled and membranes were fixed in
96% methanol for two minutes. The membranes were rinsed
in distilled water and subsequently stained in Giemsa for two
minutes, followed by two washing steps. Then, the cells on the
upper side of the filters were cleaned off. Cells in the filter
were counted under a microscope at a magnification of 20. To
allow for comparison between multiple assays, the data were
normalised and expressed as migration rate of the cells com-
pared with the control chamber.
Tumorigenicity studies in SCID mice
The study was approved by the Animal Assurance Agency
R5002-01 (ethical permits N421/04 and N235/05). MJ1105-
hCAP18 and MJ1105-eGFP cells were trypsinised and sus-
pended in PBS/1 mM magnesium chloride at 50 million/ml.
Ten million cells (200 μl) were injected subcutaneously into
the mouse. These cells require oestrogen for tumour forma-
tion, so slow-release 17-β oestradiol pellets (1.7 mg total
dose; Innovative Research of America, Sarasota, FL, USA)
were implanted the day before tumour cell injection. The test
group injected with the hCAP18 transgenic cell line and the
group injected with the control cell line each consisted of five
mice. Mice were observed daily and palpated for tumour for-
mation twice a week. Mice were sacrificed when the tumour
reached about 1 cm3 in size. Tumours were excised and snap
frozen, and used for immunohistochemistry, protein and RNA
extraction as described. For detection of metastasising cells,
spleen and liver were disaggregated to single cell suspen-
sions, and after lysis of erythrocytes with 0.17% ammonium
chloride and removal of debris by centrifugation, analysed for
the presence of eGFP expressing cells by FACS analysis.
Results
hCAP18 expression correlates with the expression of 
ERBB2 and is associated with lymph node metastasis in 
estrogen receptor positive human breast cancer
Previously we have shown that hCAP18 mRNA and protein
are overexpressed in human breast cancer samples [17]. To
explore its possible association with tumour development, we
investigated hCAP18 mRNA levels in an extended panel of
human breast cancer samples (n = 109). Results of quantita-
tive RT-PCR demonstrated that the average level of hCAP18
mRNA expression was at least one order of magnitude higher
in breast cancer tissues in comparison with normal breast tis-
sue (Figure 1a,b). Of note, only eight out of the 109 tumours
expressed hCAP18 within the low range of control samples
and none of these tumours had lymph node metastases at the
time of surgery [see additional data file 1]. Stratifying the
patient material based on ER expression, and the presence of
lymph node metastasis we found that hCAP18 expression
was significantly higher (p < 0.001) in ER-positive tumours (n
= 38) with lymph node metastases than in tumours without
lymph node metastasis (n = 42) associating the expression of
hCAP18 with metastasis formation in breast cancer (Figure
1a). Although the expression of hCAP18 was significantly
greater in ER-negative tumours compared with control tissues,
there was no clear association with lymph node metastasis at
the time of primary surgery (Figure 1b). However, our resultsPage 3 of 13
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lymph node metastasis at least in ER-positive human breast
cancer.
Amplification and overexpression of the tyrosine kinase recep-
tor gene ERBB2 is a hallmark of metastatic development in
breast cancer [21]. Because LL-37 has been linked to EGFR
signalling [7,8], we investigated if increased hCAP18 expres-
sion was associated with changes in ERBB2 levels. Our data
demonstrate a highly significant correlation between the
expression of both genes in ER-positive as well as in ER-neg-
ative tumours (Figure 1c,d). Neither ERBB2 nor hCAP18 tran-
scription levels in breast cancer patients correlated with
relapse or mortality after 5 to 10 years of follow-up (data not
shown).
hCAP18 and ErbB2 are functionally connected in breast 
cancer cells
To investigate whether hCAP18 regulates the expression of
ERBB2, we established a transgenic cell line derivative from a
low malignant ER-positive breast cancer line, MJ1105 [22],
which has no amplification of ERBB2 and expresses hCAP18
at a low levels similar to those of normal mammary tissue. The
low expression of ERBB2 remained unchanged [see addi-
tional data file 2], so we further investigated whether LL-37
had a functional influence on ERBB2. And because LL-37 is
reported to induce phosphorylation of MAPK via the EGFR [7],
we assessed its effect on signaling through ErbB2 using
recombinant HRG as positive control. The experiments were
carried out in MJ1105 and in the ER-positive breast cancer
line ZR75-1 [22]. Both LL-37 and HRG induced phosphoryla-
tion of ERBB2 and MAPK in both cell lines (shown in Figure 2
for ZR75-1). When LL-37 and HRG were added together, a
synergistic increase in MAPK phosphorylation was observed.
Figure 1
hCAP18 transcript levels in relation to ERBB2 levels, lymph node status and oestrogen receptor (ER) status. All transcription levels determined by 
real-time reverse transcriptase PCR are displayed relative to the mean of four control samples. (a) Significantly higher levels of hCAP18 transcript 
for lymph node positive compared with lymph node-negative ER-positive patients (p < 0.001). (b) No significant difference in hCAP18 levels with 
respect to lymph node status was observed for ER-negative patients (a, b) filled markers and error bars represent geometric means and 95% confi-
dence intervals. The association between hCAP18 levels and lymph node status was significantly different for (a) ER-positive and (b) ER-negative 
patients (p = 0.01). (c, d) Significant correlation between levels of hCAP18 and ERBB2 was observed in all groups, whether (c) ER positive or (d) 
ER negative, and irrespective of lymph node status (squares versus circles).Page 4 of 13
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Figure 2
LL-37 synergistically enhances Heregulin-induced mitogen-activated protein kinase (MAPK) phosphorylation through the ERBB2 receptorli i i i  r t i  ki  ( ) phosphorylation through the ERBB2 receptor. (a) Phos-
phorylation of ERBB2 (upper panel) and MAPK (lower panel) by treatment of ZR75-1 cells with LL-37 and Heregulin β3 (HRG) on their own and in 
combination. The diagram shows the mean phosphorylation level as evaluated by Western blot analysis, normalised against Ponceau staining and 
relative to untreated samples. On the left side is shown one representative of the triplicates used for evaluation. The lower rows show Western blots 
against total ERBB2 and MAPK, demonstrating an unaltered protein level, and Ponceau staining of the corresponding sections of the blot. (b) Inhi-
bition of MAPK activation in ZR75-1 by the ERBB inhibitor PD153035 but not by pertussis toxin or metalloprotease inhibitor GM6001. The arrow 
points to the histogram for PD153035 treatment. (c) LL-25 inhibits the LL-37 dependent activation of MAPK. Experiments were performed in the 
MJ1105 control cell line using HRG at 2 ng/ml, and by varying the concentrations of both LL-37 and LL-25 as displayed. The diagram shows the lev-
els of MAPK phosphorylation relative to the conditions of 2 μM LL-37. (d) Synergistic effect between HRG and endogenous production of trans-
genic hCAP18 in the MCF-7 derivative MJ1105. For all experiments, the Ponceau staining used for normalisation is shown. All conditions were run 
in triplicates (n = 3), and in addition repeated at least on one independent occasion.
Breast Cancer Research    Vol 11 No 1    Weber et al.Immunoblotting showed that the amount of ERBB2 and ERK
1/2 protein remained unchanged, indicating that LL-37 and
HGR did not affect their expression, only their activation (Fig-
ure 2a).
A scrambled version of LL-37 [23] was without activity (not
shown), confirming the specificity of LL-37 in our experiments.
For LL-37, a micromolar concentration was required to
achieve significant synergistic activity (data not shown). This
concentration range of LL-37 was previously demonstrated to
increase proliferation and migration of epithelial cells and to
induce angiogenesis [8,17,23].
PD153035, an inhibitor of tyrosine kinase activity of the ERBB
family, blocked the HRG dependent MAPK activation (Figure
2b) at 2.5 μM. The activation of MAPK induced by LL-37 on its
own was maintained, but the synergistic effect seen with both
substrates was lost in the presence of PD153035 (Figure 2b).
At 20 nM, a concentration sufficient to completely block the
EGFR [24], PD153035 only caused a slight inhibition. Thus
the EGFR does not seem to contribute significantly to the
observed effect.
LL-37 has been shown to activate cell signalling through per-
tussis toxin sensitive G proteins [8,10,23]. The activation of
EGFR by LL-37 was previously demonstrated to involve the
release of heparin-bound EGF by metalloproteases that were
blocked with the inhibitor GM6001 [7]. Neither of these alter-
natives, however, seemed responsible for our findings, since
the effect of LL-37 both in absence and presence of HRG was
unaffected by pertussis toxin or GM6001 (Figure 2b). We also
used the WRW4, an antagonist of LL-37 at the G-protein cou-
pled receptor FPRL1 [25], and inhibitors against PKA, PKC
and c-src, which can perform a crosstalk between ERBB2 and
a G-protein coupled receptor [26]. In addition we tested inhib-
itors against reactive oxygen species, which can influence
tumourigenicity by activating EGFR-related pathways [27].
The synergistic effect between LL-37 and HRG on the level of
activated MAPK was unaffected by these treatments [see
additional data file 3].
LL-25, a synthetic derivative of LL-37, lacking the 12 C-termi-
nal amino acids, had a minimally stimulatory effect on the phos-
phorylation of MAPK on its own (not shown), but strongly
inhibited the effects induced by LL-37 (Figure 2c). The inhibi-
tion was dependent on the LL-37/LL-25 molar ratio, and not
on the absolute concentration of LL-25, suggesting that LL-25
serves as a competitive inhibitor of LL-37. A scrambled version
of LL-37 [23] was without activity (not shown), confirming the
specificity of LL-37 in our experiments.
MJ1105 cells showed a similar behaviour in this assay. How-
ever, the response to HRG was strongly elevated when
hCAP18 was overexpressed from a transgene, indicating that
transgenic expression partially replaced the exogenous addi-
tion from LL-37 (Figure 2d).
LL-37 alters anchorage independent growth morphology 
of breast cancer cells
To investigate whether LL-37 influences tumour cell behav-
iour, we studied the effect of LL-37 on colony formation of
MJ1105, with or without transgenic hCAP18 expression, and
ZR75-1 in soft agar. LL-37 in the presence or absence of HRG
did not significantly affect the number of colonies, but pro-
foundly affected their morphology irrespective of the cell line.
In the presence of LL-37, colonies became less compact and
were surrounded by satellites (shown for MJ1105 in Figure 3).
This observation shows that LL-37 impacts the growth pattern
of breast cancer cells and suggests that LL-37 promotes a
migratory cell phenotype. The addition of 1 μM LL-25, which
was sufficient to substantially inhibit the LL-37-induced MAPK
phosphorylation, significantly reduced the number of dis-
persed colonies (Figure 3). The three cell lines behaved simi-
larly [see additional data file 4]. Thus, the LL-25 peptide
inhibited not only MAPK activity induced by LL-37, but also the
soft agar growth morphology of breast cancer cells.
Figure 3
LL-37 induces morphological changes in MJ1105 soft agar clonesl i l  in J1105 soft agar clones. The 
upper row shows an example of a colony in absence and in presence of 
LL-37. For the quantitative evaluation displayed in the diagram, cell cul-
ture experiments for each condition (n = 8) were arranged in a factorial 
design and the resulting data analysed by analysis of variance 
(ANOVA), the significance level set to α = 0.05. The proportion of cell 
colonies with LL-37 induced morphological alterations was significantly 
lower in presence of LL-25 (p < 0.01). The experiment was repeated 
on three independent occasions.Page 6 of 13
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The change in cell colony phenotype was suggestive of an
influence of LL-37 on cell migration, so we evaluated the effect
of LL-37 on MCF7 breast cancer cell migration using a
Boyden chamber assay. In this assay, the presence of 2 μM
LL-37 tripled the number of migrating MCF7 cells (p < 0.001),
compared with controls. In accordance with our in vivo data,
the presence of LL-25 (1 μM) abolished the migratory effect of
LL37 (p < 0.01), thus confirming its inhibitory potential,
although on its own LL-25 did not have a significant effect on
cell migration (Figure 4).
Overexpression of hCAP18 in breast cancer cells 
enhances metastasis formation in SCID mice
To extend our in vitro findings to in vivo tumour growth and
metastasis, we investigated the effect of hCAP18/LL-37 in a
xenograft model. To this end, we established primary tumours
with hCAP18 transgenic and control derivatives of MJ1105
cells in severe combined immunodeficiency (SCID) mice and
monitored tumour growth and metastasis formation (Table 1
and Figure 5). As determined by RT-PCR, the transgenic cell
line expressed hCAP18 at the level of high expressing breast
tumours, whereas the expression of the control cell line was at
the level of unaffected breast tissue (Figure 5b).
In vitro, the colony formation assay did not show any distin-
guishable features for the transgenic lines [see additional data
file 4]. In the mouse, however, we observed a significant differ-
ence between transgenic and control cells in metastasis for-
mation (Table 1.) Four out of five mice injected with the
hCAP18-overexpressing breast cancer cells developed
metastases, three of them in multiple forms and/or loci (Table
1). Metastases were detected in lymph nodes, abdominal
tumours, ascites fluid and EGFP-expressing MJ1105-hCAP18
cells in spleen and liver (Figure 5a and Table 1). In contrast,
only one lymph node metastasis was detected in one of the
mice injected with the control cells (Table 1), and this was
located on the same side as the primary tumour. The presence
of human breast cancer cells in all tumours and metastases
was verified by detecting the expression of eGFP fluorescent
marker in the ascites fluid (Figure 5a), and by immunohisto-
chemistry with anti-HLA-ABC antibodies (not shown) on the
solid tumours.
High expression of hCAP18 in all primary and secondary
tumours of test mice injected with MJ1105 hCAP was verified
by RT-PCR and confirmed by immunohistochemistry (Figure
5b and additional data file 5). Some tumour regions stained
weakly, even with HLA staining (not shown), indicating infiltra-
tion by mouse cells. Interestingly, in primary tumours from the
control cell line, RT-PCR analysis of hCAP18 mRNA showed
a two-fold elevation compared with the expression in cell cul-
ture (Figure 5b). Immunohistochemistry revealed that hCAP18
was produced in small foci within all primary control tumours,
thus confirming that spontaneous, local upregulation of
hCAP18 occurred in these tumours in vivo (Figure 5b). No
alteration of the ERBB2 transcription level, compared with the
parental cell lines, was detected in control or test samples
[see additional data file 2].
Western blot analysis revealed significant differences
between primary tumours in test and control mice. The level of
phosphorylated MAPK was higher (p < 0.05) in hCAP18
transgenic tumours compared with the control group. In the
transgenic tumours, a decrease of phosphorylated p185
ERBB2 was found (Figure 5c) whereas a band of 65 kDa was
increased in intensity, indicative of ERBB2 degradation. An
additional blot using antibodies against total ERBB2 showed
the same image and thus confirmed that the bands indeed
were derived from ERBB2 (not shown).
Discussion
Expanding from our previous findings, we demonstrate that
hCAP18 is highly expressed in breast cancer. Only few
tumours expressed hCAP18 mRNA within the range of control
samples, and none of these showed evidence of metastases.
Stratifying the material we found that in the ER-positive
Figure 4
LL-37 at 2 μM increases the migration of MCF-7 breast cancer cells in a Boyden Chamber say
a Boyden Chamber assay. The stimulatory effect induced by LL-37 was 
abrogated when LL-25 at 1 μM was added together with LL-37 in the 
lower chamber. Control experiments were with medium only in the 
lower chamber, or with LL-25 in the medium, respectively. The results 
are given as mean ± standard error of the mean, n = 4. * p < 0.05, ** p 
< 0.01, ns = non significant.Page 7 of 13
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Figure 5
Overexpression of hCAP18 in MJ1105 cells increases metastasis formation in severe combined immunodeficiency (SCID) mice. (a) Metastasis for-
mation displayed in a mouse injected with MJ1105-hCAP18 cells compared with control mouse treated with MJ1105 lacking hCAP18. The right 
panel shows tumour cells from ascites fluid detected by fluorescent transgene-coupled enhanced green fluorescent protein (eGFP) expression. (b) 
Expression analysis of hCAP18/L-37 in mouse tumours. (Left) Immunohistochemistry with anti-LL-37 antibodies demonstrating strong expression in 
transgenic tumours, and minor local induction in control tumours. Right, the expression of hCAP18 mRNA determined by reverse transcriptase PCR 
in tumours and transgenic cell lines. All comparisons are made to the expression of MJ1105 control cell line, which is set to one. (c) Western blot 
analysis demonstrates increased mitogen-activated protein kinase (MAPK) phosphorylation and increased degradation of phosphorylated ERBB2, in 
hCAP18 transgenic primary tumours compared with control primary tumours. On the left side of the blot, the control cell line is shown for compari-
son. Diagrams to the right illustrate the expression levels for respective tumour group, their statistic significance (two-tailed t-test, equal variance) 
indicated by asterix.
Available online http://breast-cancer-research.com/content/11/1/R6tumours, but not in ER-negative tumours, the level of hCAP18
expression was significantly higher in patients with lymph node
metastasis. ER positivity is reported to be associated with
more benign disease, so our findings may seem contradictory.
However, breast cancer biology and heterogeneity remain
insufficiently understood and still today, no single marker has
been identified that will consistently predict prognosis. In fact,
microarray studies have demonstrated that ER-positive
tumours are a highly heterogeneous group, and that the overall
favourable prognosis attributed to ER-positive status proved
valid for a subgroup of tumours, whereas another group of ER-
positive tumours was associated with poor outcome [28].
Of particular interest in this context is the recent identification
of a 'wound response signature' that from established biomar-
kers such as tumour grade, lymph node status and ER-status,
was shown to independently predict prognosis in breast can-
cer with significantly higher accuracy than established risk fac-
tors [29]. Specifically, it was shown that the expression of
such a wound signature in breast tumours significantly
affected metastasis potential and reduced survival. Consider-
ing that LL-37 is emerging as an integral part of the innate
reaction to wounding, being rapidly and strongly upregulated
in response to injury and also involved in the healing process,
it can be hypothesised that similar cellular programs are at play
in cancer progression.
Gene amplification and protein overexpression of the tyrosine
kinase receptor ErbB2 is considered a hallmark of metastatic
development and poor outcome in breast cancer [21]. Our
data demonstrate a significant correlation between the tran-
scription levels of hCAP18 and ERBB2 genes in ER-positive
as well as in ER-negative tumours. Despite this, there was no
correlation for hCAP18 or ERBB2 expression and survival at
five-year follow-up in any of the groups, again underscoring the
limitations using single transcription markers in predicting dis-
ease outcome.
The control breast cancer cells used for the mouse study have
only marginal expression of hCAP18 when grown in vitro.
However, after forming primary tumours at the site of cell injec-
tion, we detected a focal upregulation of hCAP18 mRNA and
protein in all mouse control tumours (Figure 5b). This phenom-
enon supports the notion that upregulation of hCAP18 is a
common event during breast cancer development, in agree-
ment with our findings in the clinical samples. Recently LL-37
was shown to stabilise the Hypoxia-Inducible factor alpha, and
consequently upregulate vascular endothelial growth factor, in
human keratinocytes [30], thus linking LL-37 to hypoxia similar
to its porcine counterpart PR39 [31]. Thus, one can hypothe-
sise that hypoxia may be the biological basis for the upregula-
tion of hCAP18/LL-37 that we observed in the mouse
tumours.
Although our studies show that hCAP18/LL-37 synergistically
enhances ERBB kinase signalling, the mechanism remains
unknown. By the use of specific inhibitors (Figure 2b), we
excluded the previously reported mechanisms of LL-37, that is
the release of EGF-like factors through activation of metallo-
proteases and/or pertussis toxin sensitive activation of G pro-
teins. Based on similar studies on lung cancer cells [19] and
in line with structural studies on LL-37 [32], it was suggested
that LL-37 causes its effects by electrostatic interactions with
the cell membrane rather than with a receptor. In our study, we
Table 1
Survey of mouse tumours derived from hCAP18 overexpressing MJ1105 and its control.








eGFP cells in 
spleen
GFP cells in liver
MJ 1105-
hCAP18
h1 43 6 × 6 × 6
h2 71 10 × 8 × 8 + +
h3 71 8 × 8 × 8 3 +
h4 75 8 × 8 × 8 3 abdominal 2 +
h5 90 8 × 5 × 4 1
MJ1105
eGFP
I1 43 10 × 10 × 10
I2 43 8 × 7 × 6
I3 90 7 × 10 × 6
I4 90 8 × 4 × 4 1
For statistical evaluation, each visible metastasis or node, or the presence of fluorescent cells in ascites/spleen or liver, are counted as one event 
each. Using the Mann-Whitney U-test, the median number of metastatic events between the groups is significant (p = 0.05). eGFP = enhanced 
green fluorescent protein.Page 9 of 13
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as a potent inhibitor of both LL-37 signalling and of LL-37-
induced migration and alteration of cancer cell colony mor-
phology. We find it difficult to understand how a fragment of
LL-37 would inhibit membrane interactions, and favour the
hypothesis that LL-37 interacts with ERBB kinases via a yet
unidentified receptor. Still, a direct effect of LL-37 on the
ERBB receptors cannot be excluded. Whatever the mecha-
nism, the fact that the effects of LL-37 can be inhibited opens
up the possibility of therapeutic targeting.
The results from the colony formation and migration assays
confirm that LL-37 expression contributes to metastases, as
hypothesised on the basis of our findings in the clinical sam-
ples. The soft agar growth pattern is indicative of cellular
behaviour and the profound phenotypic changes induced by
LL-37 peptide treatment, most likely reflect an enhanced
migratory and invasive capacity in these cells. The colony mor-
phology induced by LL-37 was strikingly similar to the growth
pattern reported for a melanoma cell line exposed to EGF-like
peptides [33], and for mammary epithelial cells overexpressing
ERBB2 [34], which was hypothesised to mirror an increased
metastatic potential [34]. The 2 μM concentration of LL-37
used in this experiment is well below cytotoxic levels and was
previously shown to stimulate cell proliferation and migration
[17,18]. In contrast, to what was recently reported for lung
cancer cells [19], we did not detect significant differences in
the number of colonies after treatment with LL-37 which may
be due to underlying biological differences between the can-
cer cell types utilised in these experiments. It should be high-
lighted that our analysis on breast tumour samples is presently
the only one to show a correlation of hCAP18 expression with
a particular tumour cell phenotype, still pending study in other
tumour types.
In accordance with the findings in the clinical studies and in
the in vitro experiments, we found a significant increase in
metastases in the SCID mice injected with the hCAP18 trans-
genic cell line. Not only did we detect lymph node metastases
but also distant metastases indicative of lymphatic as well as
haematic spread of tumour cells. The control breast cancer
cells used for the mouse study have only marginal expression
of hCAP18 when grown in vitro. However, after forming pri-
mary tumours at the site of cell injection, we detected a focal
upregulation of hCAP18 mRNA and protein in all mouse con-
trol tumours indicating that local upregulation of hCAP18
occurred when these tumours formed in vivo (Figure 5b). This
phenomenon supports the notion that upregulation of
hCAP18 is a common event during breast cancer develop-
ment, in agreement with our findings in the clinical samples.
Western blot analysis of the mouse tumours confirmed that
the MAPK activation by hCAP18/LL-37 that we observed in
vitro reflects events of in vivo tumourigenesis. The partial deg-
radation of ERBB2 in overexpressing tumours is worthy of
note. A reduced amount of intact protein, at a constant tran-
scription rate, is characteristic of receptor degradation after
activation and internalisation, as reported for ERBB2 following
long-term ligand activation [35]. Truncated versions of ERBB2
have been shown to actively participate in signalling [36] and
to be resistant to trastuzumab treatment in breast cancer [37].
We did not detect the presence of truncated ERBB2 in our
MAPK activation assays, which may reflect that the activation
time might have been too short to induce degradation. How-
ever, the cellular environment should also be considered: in
the mouse the extracellular proteins or domains on the tumour
cell surface are exposed to proteases from the surrounding
stroma, which might contribute to their degradation, or in the
case of hCAP18, its activation. This would also explain why
transgenic hCAP18 did not appear to alter the properties in
the colony formation assay, but still induced metastasis forma-
tion in the mouse. In correlation with this hypothesis, recent
studies show that the expression of metalloprotease MMP9
from the tumour surrounding stroma, unlike its expression in
tumour cell cytoplasm, correlates with unfavourable prognosis
in ERBB2 positive breast cancer [38].
The correlation between hCAP18 and ERBB2 expression that
was observed in the human tumours did not occur in vitro or
in the mouse model. We favour the hypothesis that the upreg-
ulation of both occurs independently, but due to their func-
tional collaboration is selected for during the evolution of
human breast cancer.
The role for hCAP18/LL-37 as a proinflammatory molecule in
innate immunity is well established. In this context, LL-37 alerts
the immune system in case of injury and microbial invasion. It
is conceivable that broad defense strategies involving
hCAP18/LL-37 evolved to provide sustained protection and
prompt repair, aiming to fully restore tissue integrity. This
would be consistent with our recent understanding of
hCAP18/LL-37 as a stimulant of cell migration and prolifera-
tion and as a promoter of wound healing [12,13]. Thus, in view
of the emerging link between chronic inflammation and cancer
[14], hCAP18/LL-37 may contribute to cancer as a novel and
versatile player, not only through its proinflammatory actions
but also through its growth-factor like properties.
The data presented herein and recent observations in lung and
ovarian cancer [18,19], point to a role for hCAP18/LL-37 in
cancer progression and spread. The underlying molecular
mechanisms, however, remain to be clarified. hCAP18/LL-37
is emerging as a multifunctional molecule progressively impli-
cated in multiple highly significant processes in cancer devel-
opment. hCAP18/LL-37 may constitute a putative therapeutic
target to prevent progression to metastatic disease.Page 10 of 13
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In summary, we show that hCAP18/LL-37 is highly upregu-
lated in breast cancer correlating with the expression of
ERBB2. In vitro, we also show that they are functionally con-
nected, in that hCAP18/LL-37 amplifies MAPK signalling
through ErbB2 and that treatment with LL-37 peptide alters
the growth phenotype and stimulates the migration of breast
cancer cells. Finally, overexpressing hCAP18 in a low malig-
nant breast cancer cell line promotes metastatic disease in a
SCID mouse model. Taken together, our data expand on
recent findings in lung and ovarian cancers and demonstrate a
novel role for the single human cathelicidin protein hCAP18/
LL-37 in breast cancer.
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